Therapeutics Novel TET2-Targeting Approaches to Induce Fetal Hemoglobin in Sickle Cell Disease and Thalassemia This technology enables increased fetal hemoglobin production to alleviate symptoms of blood disorders by modulating TET2 enzyme activity through targeted mutation and pharmacological suppression.… Reference ID: 24-T-028
Diagnostics Therapeutics Tumor Aneuploidy Score As A Predictor Of Immunotherapy Response Tumor aneuploidy scoring delivers improved immunotherapy response prediction, enhancing personalized cancer treatment by providing prognostic insights beyond existing biomarkers like tumor mutational burden. The… Reference ID: 23-T-172
Therapeutics Modular Glycopolymer Technology for Antigen-Specific Immune Tolerance This technology achieves significant reduction of anti-drug antibody responses through synthetically mannosylated antigen conjugation that induces antigen-specific humoral tolerance by enhancing hepatic immune tolerance… Reference ID: 18-T-048
Therapeutics A Modular LOX-Mediated Delivery Platform for Solid Tumor Immunotherapy Enhanced tumor regression and immune activation through localized retention of engineered cytokines and chemokines by lysyl oxidase-mediated crosslinking to the tumor extracellular matrix improves… Reference ID: 26-T-065
Agricultural Cleantech Medical Devices Research Tools Therapeutics Adaptive Microbial Platform For Gut Health, Biofuel, And Soil Productivity A novel biomaterial platform designed to enhance microbial modulation, featuring tunable chemical, mechanical, and optical responsiveness for applications in health, agriculture, and industry. The… Interests: Chemical Synthesis, Medical, Microbiome Reference ID: 23-T-052
Medical Devices Therapeutics Lithium-Driven Neural Inhibition Devices For Chronic Pain And Local Anesthesia An implantable bioelectronic device platform enabling targeted, programmable inhibition of neural activity through lithium ion delivery, offering durable local anesthesia and pain relief without… Reference ID: 25-T-086 Desired Partnership: Co-development, Licensing IP: Patent Pending
Research Tools Therapeutics Rapid Selection Of High-Value Internalizing Binders For Targeted Therapeutics Lentiviral display platform engineered to directly select and enrich antibodies based on their ability to induce receptor-mediated endocytosis, thereby streamlining the discovery of highly… Interests: Antibody, Antibody Reference ID: 26-T-188 Desired Partnership: Co-development, Licensing IP: Patent Pending
Research Tools Therapeutics A Programmable Translational Activator Platform For Restoring Endogenous Protein Expression In Haploinsufficiency Disorders The CIRTS-4GT3 platform is a compact, programmable system that uses guide RNAs and human protein domains to boost production of specific proteins in cells,… Interests: Gene Therapy Reference ID: 24-T-204 Desired Partnership: Co-development, Licensing IP: Patent Pending
Therapeutics Oral Systemically-Bioavailable Butyrate For Treating Inflammatory Diseases Method to attach butyrate to amino acids, allowing it to bypass gut metabolism and enter the bloodstream, increasing its bioavailability and enabling effective treatment… Interests: Allergy, Autoimmune, Chemical Synthesis, Gastrointestinal, Inflammatory, Microbiome Reference ID: 21-T-136 Desired Partnership: Co-development, Licensing IP: Patent Pending
Research Tools Therapeutics Nucleic Acid Enrichment And Sequencing Method For Detecting Off-Target Base Editing Events Inrich-seq is a new method that selectively enriches and sequences inosine-containing DNA or RNA, enabling highly sensitive, genome-wide detection of off-target effects from adenine… Interests: Drug Screening, Gene Therapy Reference ID: 25-T-225 Desired Partnership: Co-development, Licensing IP: Patent Pending
Diagnostics Therapeutics Amphiregulin Screening And Inhibition Methods For Reducing Metastasis And Enhancing Radiotherapy Efficacy Methods to improve radiotherapy by blocking the protein Amphiregulin (AREG), which helps tumors resist treatment and spread. Inhibiting AREG enhances anti-tumor effects and reduces… Interests: Biomarker, Oncology Reference ID: 25-T-105 Desired Partnership: Co-development, Licensing IP: Patent Pending
Therapeutics Antibody-Polymer Conjugates For Engaging T Cells To Destroy Cancer Cells An antibody linked to a polymer that connects T cells to cancer cells enabling broad cancer targeting and effective tumor cell killing without needing… Reference ID: 25-T-108 Desired Partnership: Co-development, Licensing IP: Patent Pending
